GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

151.76B

Vuru Grade

76.10/100

Current Price

$101.89
+0.82 (+0.81%)

Growth Price

$107.39
Undervalued by 5.39%

Stability Price

$42.59
Overvalued by 58.20%

Company Metrics

  • 13.86 P/E
  • 6.05 P/S
  • 9.81 P/B
  • 7.35 EPS
  • 43.15% Cash ROIC
  • 1.76 Cash Ratio
  • 0 / N/A % Dividend
  • 13.64M Avg. Vol.
  • 1.49B Shares
  • 151.76B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Better Dividend Stock: AbbVie or Gilead Sciences, Inc.?
Motley Fool - Mar 23, 2015
AbbVie (NYSE: ABBV ) and Gilead Sciences (NASDAQ: GILD ) are two dividend-paying healthcare companies that perhaps underscore these issues best.
Which Dividend Paying Stock is Better: Gilead Sciences (NASDAQ:GILD) or ... - WallStreet.org
Here's How Gilead Sciences Inc And AbbVie Inc Trumped Merck & Co Out of ...
Bidness ETC - 20 hours ago
Merck & Co., Inc.(NYSE:MRK)'s combination drug of grazoprevir and elbasir for the treatment of hepatitis C virus infection, has little chance of survival in a market already dominated by major competitors including Gilead Sciences Inc (NASDAQ:GILD) and ...
Special News Alert: Novavax, Inc. (NASDAQ:NVAX), Gilead Sciences Inc ... - Market News Call
Japan's Ministry of Health, Labour and Welfare Approves Gilead's Sovaldi ... - Business Wire (press release)
Gilead Sciences, Inc. Issues Warning After Hepatitis Patient Taking Heart Drug ...
Bidness ETC - Mar 23, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) might face further criticism beyond its pricing strategy, as the company announced that nine patients who had been taking its hepatitis C drugs Sovaldi or Harvoni, as well as amiodarone, a heart treatment drug, ...
William Blair Remains Positive on Gilead Sciences, Inc. Following the Release ... - Smarter Analyst
Gilead Sciences, Inc. (NASDAQ:GILD) Shares declined after company disclosed ... - Inside Trade
In Case You Missed It, Gilead Sciences, Inc.'s “Bad” News Is Actually Great
Motley Fool - Mar 10, 2015
The FDA approval in December of AbbVie's (NYSE: ABBV ) hepatitis C therapy Viekira Pak and the ensuing price cuts by AbbVie Inc and market leader Gilead Sciences (NASDAQ: GILD ) to win market share are weighing down Gilead Sciences' share price.
Gilead Sciences, Inc.: Still In The Lead Or Lagging Behind? An Algorithmic ... - Seeking Alpha (registration)
Gilead Sciences, Inc. Continues To Outperform AbbVie Inc - Bidness ETC
Should Gilead Sciences Inc.'s Slowing Growth Concern Investors?
Motley Fool - Mar 15, 2015
The failure of the market to buy into Gilead Sciences' (NASDAQ: GILD ) amazing growth story is a flat-out mystery in the eyes of many investors.
Slow Growth of Gilead Sciences, Inc. (NASDAQ:GILD); Good or Bad For Investors? - WallStreet.org
Most Active Weekly Options: American Express Company and Gilead Sciences ...
Schaeffers Research (blog) - Mar 24, 2015
Receiving notable attention is AXP's weekly 3/27 79.50-strike put, which is apparently being bought to open. In other words, those purchasing new positions expect American Express Company to breach $79.50 by week's end, when the series expires.
Gilead Sciences: Go With Growth
Seeking Alpha (registration) - Mar 17, 2015
Research-based Gilead Sciences Inc (NASDAQ: GILD) is committed to the discovery, development, and commercialization of treatments/therapies to battle various infections and diseases including HCV, HIV, liver disease, cardiovascular issues, and various ...
Experts Talking Gilead, Not Bubbles At Detroit's Engage Conference
Benzinga - 47 minutes ago
... "bubble" during the presentation, but they did discuss biotechnology. "The biotech sector has been on fire," Link said, but warned against overvalued smaller companies.
Argus Sees 'Strong Prospects' For Gilead Sciences
Benzinga - Mar 20, 2015
Argus reaffirmed its Buy rating on Gilead Sciences, Inc. (NASDAQ: GILD) Thursday and maintained a $130 price target on "strong prospects for antiviral and oncology drugs.
Here's Why Gilead Sciences, Inc. (GILD) Has Been Reaffirmed A “Buy” At Argus - Bidness ETC
Gilead Warns After Hepatitis Patient on Heart Drug Dies - Bloomberg
AbbVie Inc Viekira Pak Prescription Volumes Climb, Gilead Sciences, Inc ...
Bidness ETC - Mar 13, 2015
Gilead Sciences, Inc. (NASDAQ:GILD) might get alarmed by the latest prescription data compiled by Symphony Health Solutions, indicating that Harvoni's prescriptions have declined, while Viekira Pak witnessed an increase in its prescriptions for the ...